Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A tri-specific antibody engages T and myeloid cells to augment anti-tumor immunity

ABSTRACT: A tri-specific antibody engages T and myeloid cells to augment anti-tumor immunity

PROVIDER: PRJNA1182282 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A tri-specific antibody engages T and myeloid cells to augment anti-tumor immunity [TCE_scRNA-seq]

Project description:A tri-specific antibody engages T and myeloid cells to augment anti-tumor immunity [TCE_scRNA-seq]

| PRJNA1185149 | ENA

A tri-specific antibody engages T and myeloid cells to augment anti-tumor immunity [bulk RNA-seq]

Project description:A tri-specific antibody engages T and myeloid cells to augment anti-tumor immunity [bulk RNA-seq]

| PRJNA1189430 | ENA

A tri-specific antibody engages T and myeloid cells to augment anti-tumor immunity

Project description:Immunologically inert tumors often resist immune checkpoint inhibitors due to a scarcity of tumor-specific T cells and the immunosuppressive microenvironment, despite pronounced and functional bystander T cell infiltration. Here, we develop a novel tri-specific T cell engager (Tri-TCE) designed in a unique format to redirect T cells while mitigating immunosuppression. Our comprehensive studies utilizing co-culture systems, patient-derived tumor suspensions (PDTSs), patient-derived tumor fragments (PDTFs), and humanized mouse tumor models, demonstrate that Tri-TCE effectively activates T cells and induces tumor cell lysis.

2025-09-15 | GSE281102 | GEO

A tri-specific antibody engages T and myeloid cells to augment anti-tumor immunity [TCE_scRNA-seq]

2025-09-15 | GSE281646 | GEO

A tri-specific antibody engages T and myeloid cells to augment anti-tumor immunity [bulk RNA-seq]

2025-09-15 | GSE282589 | GEO

Succinate preserves CD8+ T cell fitness to augment anti-tumor immunity

Project description:Succinate preserves CD8+ T cell fitness to augment anti-tumor immunity

| PRJNA1271764 | ENA

Interleukin-4 modulates type I interferon to augment anti-tumour immunity

Project description:Interleukin-4 modulates type I interferon to augment anti-tumour immunity

| PRJNA1224251 | ENA

Interleukin-4 modulates type I interferon to augment anti-tumour immunity [scRNA-Seq]

Project description:Interleukin-4 modulates type I interferon to augment anti-tumour immunity [scRNA-Seq]

| PRJNA1224250 | ENA

A basigin antibody modulates MCTs to impact tumor metabolism and immunity

Project description:Lactate metabolism and signaling intricately intertwine in the context of cancer and immunity. Basigin, working alongside monocarboxylate transporters MCT1 and MCT4, orchestrates the movement of lactate across cell membranes. Despite promising potential in treating aggressive tumors, the impact of basigin antibodies on these interactions remains unclear. Our research sheds light on this complex interplay: basigin positively modulates MCT activity. A basigin antibody transforms basigin into a negative regulator of MCTs. The antibody suppresses lactate transport and enhances anti-tumor immunity in vitro and in vivo. Furthermore, antibody alters metabolic profiles in PDOs-NSCLCs and T cells. Cryo-EM structure analysis and molecular dynamics simulations unveil that MCT1’s turnover rate is influenced by the flexibility of basigin’s Ig2 domain. By restricting Ig2 flexibility, antibody reduces MCT1 turnover. These findings underscore the promise of basigin antibodies in tumor combat by influencing metabolism and immunity and the value of shared ancillary subunits in targeting heteromeric transporters.

2025-05-14 | GSE268751 | GEO

Spermine Synthase Engages in Macrophages M2 polarization to Sabotage Antitumor Immunity in Hepatocellular Carcinoma

Project description:Spermine Synthase Engages in Macrophages M2 polarization to Sabotage Antitumor Immunity in Hepatocellular Carcinoma

| PRJNA1162468 | ENA